PremiumThe FlyDyne at ‘attractive entry point’ following pullback, says Chardan Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly Dyne Therapeutics: Strategic Shift to vHOT and FDA Support Bolster Buy Rating PremiumThe FlyDyne Therapeutics assumed with an Outperform at Raymond James Promising Potential and Growth Prospects for Dyne Therapeutics: Buy Rating Affirmed Dyne Therapeutics Elects New Directors at Annual Meeting PremiumThe FlyDyne Therapeutics price target lowered to $38 from $46 at H.C. Wainwright Dyne Therapeutics: Strategic Advancements and Strong Financials Support Buy Rating Dyne Therapeutics reports Q1 EPS (81c), consensus (84c) 
